Loading…
← CockpitCompetitor Analysis › IBRX ImmunityBio IncOpen in the cockpit ↗

ImmunityBio IncIBRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.

Momentum weak 26
Mkt cap
$7.13B
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$96.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$6.70
1D+7.0%
1W+0.5%
1M-23.6%
3M-14.5%
6M-16.8%
YTD+238.4%
1Y+230.1%
ATR %10.0%
Beta1.39
52w lowhigh46.1% off high

What ImmunityBio does

Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.

Earns from sales of Anktiva, instilled into the bladder in a urologist's office alongside the standard BCG treatment. Spending far exceeds sales while the launch builds, and the company has been funded largely by chairman Patrick Soon-Shiong, who holds a majority of the shares. The rest of the pipeline is not yet generating sales.

Products and services

  • Anktiva (bladder cancer)
  • Cell-therapy/NK-cell pipeline
  • Cancer-vaccine pipeline

Customers

  • Urologists/oncologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Immuno-oncology

What could go right

  • Anktiva commercial ramp in bladder cancer
  • Broader immuno-oncology pipeline maturing

What could go wrong

  • High cash burn ahead of broad profitability
  • Manufacturing/supply execution risk

Moat: narrow (IP / patents, regulatory licence). Approved therapy for a specific unmet niche (BCG-unresponsive bladder cancer) ahead of most pipeline rivals.

Headquarters: San Diego, California, United States · Founded: 2014 · Employees: 691

Named competitors

ImmunityBio at a glance

Size ImmunityBio (IBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.13B, the 950th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.70 on 18 Nov 2026.

Performance Over six months the shares fell 16.8%, against +5.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 121.2% over the last twelve months (peer median +8.9%); the operating margin is -150.2% (peer median 15.1%).

Valuation It trades at 44.3× enterprise value to sales against a peer median of 4.8× (2nd most expensive of 19).

Short interest Short interest is 11.9% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 107IBRX 87
Six months, rebased to 100: ImmunityBio against the median of its 20 peers (local-currency closes).

ImmunityBio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$183M$113M$14.7M$622,000$240,000
Revenue growth—+668%+2,271%+159%—
Gross profit$164M$97.0M-$2.81M-$17.9M-$24.0M
EBITDA-$258M-$241M-$327M-$343M-$326M
Net income-$1.11B-$351M-$414M-$583M-$417M
Free cash flow-$297M-$309M-$398M-$397M-$416M
Capital expenditure$9.53M$4.25M$6.89M$30.6M$99.4M
Total debt$1.30B$845M$790M$884M$725M

Quarterly statements and history in the cockpit →

ImmunityBio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%CYTK6821BANB99264528CORTKNSAGRF600196000963ALKEMAMRXORKA0126Z0ALKSBLTEGLENMARKIBRX6-month return →1-month return →
Up and to the right = strong over both horizons. ImmunityBio is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×20×40×60×CYTK6821BANB99264528CORTKNSAGRFALKSGLENMARKIBRXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ImmunityBio is the large dot.

ImmunityBio competitors and peer comparison

Head to head with its named competitors (IBRX vs MRK vs JNJ vs URGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
ImmunityBio IBRX$7.13B-17%+121%-150%44.3×n/a
Merck & MRK$340B+23%+5%18%5.7×8.3%
Johnson & Johnson JNJ$656B+20%+8%26%6.9×3.7%
UroGen Pharma URGN$1.46B-1%+159%-12%6.3×n/a
CG Oncology CGON$7.15B+24%+184%-4,294%1,000.7×n/a

How ImmunityBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ImmunityBio against its 20 peers (data as of 18 Nov 2026)
MeasureIBRXPeer medianRank in peer set
1-month return-23.6%+2.2%3rd lowest of 21
6-month return-16.8%+5.9%5th lowest of 20
Distance from 52-week high-46.1%-14.9%4th lowest of 21
Revenue growth (TTM)+121.2%+8.9%highest of 18
Operating margin-150.2%15.1%2nd lowest of 19
EV / Sales44.3×4.8×2nd most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%44.3×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%64.3×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%5.8×n/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%8.6×n/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%12.9×n/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%2.1×-6.8%+10.8%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%7.3×23.9%+16.6%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%7.3×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%2.4×7.1%+7.1%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%2.1×2.9%+6.6%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%1.1×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%4.1×25.0%+10.7%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%3.4×17.2%+8.7%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%1.9×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%3.5×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%5.9×n/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%5.0×32.5%+7.3%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%7.4×7.3%+12.6%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%4.7×27.3%+9.4%

Questions

Who are ImmunityBio's main competitors?
Named competitors: Merck (MRK), Johnson & Johnson (JNJ), Ferring Pharmaceuticals (private or unlisted), UroGen Pharma (URGN), CG Oncology (CGON), enGene Holdings (private or unlisted). The cockpit's measured peer set (industry) also includes Cytokinetics (CYTK), Asymchem Laboratories (Tianjin) (6821.HK), Bachem (BANB.SW), Akeso (9926.HK), ONO Pharmaceutical (4528.T), Corcept Therapeutics (CORT).
Is ImmunityBio expensive compared with its peers?
On ev / sales it trades at 44.3× against a peer median of 4.8×, 2nd most expensive of 19 in its peer set.
How has ImmunityBio stock performed?
Over six months to 18 Nov 2026 the shares returned -16.8% against +5.9% for the median peer; over one year +230.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.